Current treatments of spinal muscular atrophy in adults

Lunn, 2008, Spinal muscular atrophy, Lancet., 371, 2120, 10.1016/S0140-6736(08)60921-6 Melki, 1994, De novo and inherited deletions of the 5q13 region in spinal muscular atrophies, Science., 264, 1474, 10.1126/science.7910982 Bürglen, 1996, Structure and organization of the human survival motor neurone (SMN) gene, Genomics., 32, 479, 10.1006/geno.1996.0147 Mailman, 2002, Molecular analysis of spinal muscular atrophy and modification of the phenotype by SMN2, Genet Med., 4, 20, 10.1097/00125817-200201000-00004 Finkel, 2017, Nusinersen versus Sham control in infantile-onset spinal muscular atrophy, N Engl J Med., 377, 1723, 10.1056/NEJMoa1702752 Mercuri, 2018, Nusinersen versus sham control in later-onset spinal muscular atrophy, N Engl J Med., 378, 625, 10.1056/NEJMoa1710504 Wijngaarde, 2020, Muscle strength and motor function in adolescents and adults with spinal muscular atrophy. Revised upper limb module in type II and III spinal muscular atrophy: 24-month changes, Neurology., 95, e1988, 10.1212/WNL.0000000000010540 Montes, 2018, Ambulatory function in spinal muscular atrophy: age-related patterns of progression, PLoS One., 13, e0199657, 10.1371/journal.pone.0199657 Coratti, 2022, Revised upper limb module in type II and III spinal muscular atrophy: 24-month changes, Neuromuscul Disord., 32, 36, 10.1016/j.nmd.2021.10.009 Rouault, 2017, Disease impact on general well-being and therapeutic expectations of European type II and type III spinal muscular atrophy patients, Neuromuscul Disord., 27, 428, 10.1016/j.nmd.2017.01.018 Gusset, 2021, Understanding European patient expectations towards current therapeutic development in spinal muscular atrophy, Neuromuscul Disord., 31, 419, 10.1016/j.nmd.2021.01.012 Osmanovic, 2020, Treatment expectations and patient-reported outcomes of nusinersen therapy in adult spinal muscular atrophy, J Neurol., 267, 2398, 10.1007/s00415-020-09847-8 Meyer, 2021, Treatment expectations and perception of therapy in adult patients with spinal muscular atrophy receiving nusinersen, Eur J Neurol., 28, 2582, 10.1111/ene.14902 Lefeuvre, 2022, Nusinersen treatment in adults with severe spinal muscular atrophy: a real-life retrospective observational cohort study, Rev Neurol (Paris)., 178, 234, 10.1016/j.neurol.2021.10.010 Wirth, 2021, Spinal muscular atrophy: in the challenge lies a solution, Trends Neurosci., 44, 306, 10.1016/j.tins.2020.11.009 Singh, 2006, Splicing of a critical exon of human Survival Motor Neuron is regulated by a unique silencer element located in the last intron, Mol Cell Biol., 26, 1333, 10.1128/MCB.26.4.1333-1346.2006 Hagenacker, 2020, Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional, multicentre, observational cohort study, Lancet Neurol., 19, 317, 10.1016/S1474-4422(20)30037-5 De Wel, 2021, Nusinersen treatment significantly improves hand grip strength, hand motor function and MRC sum scores in adult patients with spinal muscular atrophy types 3 and 4, J Neurol., 268, 923, 10.1007/s00415-020-10223-9 Maggi, 2020, Nusinersen safety and effects on motor function in adult spinal muscular atrophy type 2 and 3, J Neurol Neurosurg Psychiatry., 91, 1166, 10.1136/jnnp-2020-323822 Pera, 2021, Nusinersen in pediatric and adult patients with type III spinal muscular atrophy, Ann Clin Transl Neurol., 8, 1622, 10.1002/acn3.51411 Coratti, 2021, Motor function in type 2 and 3 SMA patients treated with Nusinersen: a critical review and meta-analysis, Orphanet J Rare Dis., 16, 430, 10.1186/s13023-021-02065-z Elsheikh, 2021, Safety, tolerability, and effect of nusinersen in non-ambulatory adults with spinal muscular atrophy, Front Neurol., 12, 650532, 10.3389/fneur.2021.650532 Vázquez-Costa, 2022, Validation of motor and functional scales for the evaluation of adult patients with 5q spinal muscular atrophy, Eur J Neurol. Elsheikh, 2021, Safety, tolerability, and effect of nusinersen treatment in ambulatory adults with 5q-SMA, Front Neurol., 12, 650535, 10.3389/fneur.2021.650535 Rich, 2022, Neurofilament levels in CSF and serum in an adult SMA cohort treated with nusinersen, J Neuromuscul Dis., 9, 111, 10.3233/JND-210735 De Wel, 2022, Biochemical and clinical biomarkers in adult SMA 3–4 patients treated with nusinersen for 22 months, Ann Clin Transl Neurol., 9, 1241, 10.1002/acn3.51625 Osmanovic, 2020, Treatment expectations and patient-reported outcomes of nusinersen therapy in adult spinal muscular atrophy, J Neurol., 267, 2398, 10.1007/s00415-020-09847-8 Vázquez-Costa, 2022, Nusinersen in adult patients with 5q spinal muscular atrophy: a multicenter observational cohorts’ study, Eur J Neurol. Meyer, 2021, Treatment expectations and perception of therapy in adult patients with spinal muscular atrophy receiving nusinersen, Eur J Neurol., 28, 2582, 10.1111/ene.14902 Bonanno, 2022, Quality of life assessment in adult spinal muscular atrophy patients treated with nusinersen, J Neurol., 269, 3264, 10.1007/s00415-021-10954-3 Wurster, 2019, Intrathecal administration of nusinersen in adolescent and adult SMA type 2 and 3 patients, J Neurol., 266, 183, 10.1007/s00415-018-9124-0 Cartwright, 2020, Intrathecal delivery of nusinersen in individuals with complicated spines, Muscle Nerve., 62, 114, 10.1002/mus.26899 Stolte, 2018, Feasibility and safety of intrathecal treatment with nusinersen in adult patients with spinal muscular atrophy, Ther Adv Neurol Disord, 11, 10.1177/1756286418803246 Grayev, 2021, A systematic review of procedural complications from transforaminal lumbar puncture for intrathecal nusinersen administration in patients with spinal muscular atrophy, AJNR Am J Neuroradiol., 42, 980, 10.3174/ajnr.A7009 Cox, 2022, Computed tomography-guided transforaminal lumbar puncture using local anesthesia and a straight 22-gauge spinal needle for intrathecal nusinersen in adults: findings in 77 procedures, Interv Neuroradiol., 28, 262, 10.1177/15910199211032842 Weaver, 2021, Transforaminal intrathecal delivery of nusinersen for older children and adults with spinal muscular atrophy and complex spinal anatomy: an analysis of 200 consecutive injections, J Neurointerv Surg., 13, 75, 10.1136/neurintsurg-2020-016058 Spiliopoulos, 2020, Computed-tomography-guided transforaminal intrathecal nusinersen injection in adults with spinal muscular atrophy type 2 and severe spinal deformity. Feasibility, safety and radiation exposure considerations, Eur J Neurol., 27, 1343, 10.1111/ene.14245 Bortolani, 2019, Intrathecal administration of nusinersen in adult and adolescent patients with spinal muscular atrophy and scoliosis: transforaminal versus conventional approach, Neuromuscul Disord., 29, 742, 10.1016/j.nmd.2019.08.007 Kizina, 2019, Clinical implication of dosimetry of computed tomography- and fluoroscopy-guided intrathecal therapy with nusinersen in adult patients with spinal muscular atrophy, Front Neurol., 10, 1, 10.3389/fneur.2019.01166 Oldenburg, 2019, Radiation exposure of image-guided intrathecal administration of nusinersen to adult patients with spinal muscular atrophy, Neuroradiology., 61, 565, 10.1007/s00234-019-02189-x Stolte, 2021, Nusinersen treatment in adult patients with spinal muscular atrophy: a safety analysis of laboratory parameters, J Neurol., 268, 4667, 10.1007/s00415-021-10569-8 Finkel, 2022, Scientific rationale for a higher dose of nusinersen, Ann Clin Transl Neurol., 9, 819, 10.1002/acn3.51562 Markati, 2022, Risdiplam: an investigational survival motor neuron 2 (SMN2) splicing modifier for spinal muscular atrophy (SMA), Expert Opin Investig Drugs., 31, 451, 10.1080/13543784.2022.2056836 Baranello, 2021, Risdiplam in type 1 spinal muscular atrophy, N Engl J Med., 384, 915, 10.1056/NEJMoa2009965 Darras, 2021, Risdiplam-treated infants with type 1 spinal muscular atrophy versus historical controls, N Engl J Med., 385, 427, 10.1056/NEJMoa2102047 Mercuri, 2022, Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial, Lancet Neurol., 21, 42, 10.1016/S1474-4422(21)00367-7 Hahn, 2022, Risdiplam Compassionate Use Program Group. Short-term safety results from compassionate use of risdiplam in patients with spinal muscular atrophy in Germany, Orphanet J Rare Dis., 17, 276, 10.1186/s13023-022-02420-8 Sergott, 2021, Risdiplam treatment has not led to retinal toxicity in patients with spinal muscular atrophy, Ann Clin Transl Neurol., 8, 54, 10.1002/acn3.51239 Mendell, 2017, Single-dose gene-replacement therapy for spinal muscular atrophy, N Engl J Med., 377, 1713, 10.1056/NEJMoa1706198 Stolte, 2022, Prevalence of anti-adeno-associated virus serotype 9 antibodies in adult patients with spinal muscular atrophy, Hum Gene Ther., 10.1089/hum.2022.054 Angelozzi, 2008, Salbutamol increases SMN mRNA and protein levels in spinal muscular atrophy cells, J Med Genet., 45, 29, 10.1136/jmg.2007.051177 Frongia, 2019, Salbutamol tolerability and efficacy in patients with spinal muscular atrophy type II, Neuromuscul Disord., 29, 517, 10.1016/j.nmd.2019.04.003 Tiziano, 2019, Longitudinal evaluation of SMN levels as biomarker for spinal muscular atrophy: results of a phase IIb double-blind study of salbutamol, J Med Genet., 56, 293, 10.1136/jmedgenet-2018-105482 Rudnicki, 2021, Reldesemtiv in patients with spinal muscular atrophy: a phase 2 hypothesis-generating study, Neurotherapeutics., 18, 1127, 10.1007/s13311-020-01004-3